A SIGNIFICANT milestone in Philippine scientific research has been achieved as the Intellectual Property Office of the Philippines (IPOPHL) officially granted a fourth patent for the groundbreaking antibiotic discovery by researchers from the University of San Agustin.
The patented invention, titled “Isolated Streptomyces griseorubens and Antibiotic Anthracycline Shunt Metabolites Therefrom,” represents a major advancement in the global fight against infectious diseases, particularly amid the growing threat of antibiotic resistance worldwide.
Breakthrough in Antibiotic Research
The discovery centers on a microbial strain, Streptomyces griseorubens, capable of producing anthracycline compounds – bioactive molecules widely recognized for their strong antibiotic and anticancer properties. Through isolation and characterization of these compounds, the research team has opened new possibilities for developing next-generation drugs that may help address drug-resistant bacterial infections.
At a time when antimicrobial resistance is considered one of the most urgent global health threats, this innovation positions Filipino scientific research as a meaningful contributor to global healthcare solutions. This innovation became possible because of the Tuklas Lunas Development Center grant from the Department of Science and Technology (DOST) through the Philippine Council for Health Research and Development.
Patent Protection and Recognition
The patent was officially granted on February 6, 2026, and will remain valid until April 15, 2041. This grants the inventors exclusive rights over the production, use, and commercialization of the invention, securing its intellectual property protection and future development potential.
The successful patent registration was facilitated through the University of San Agustin – Innovation and Technology Support Office (ITSO) and the expertise support of TechMatch Asia Inc., ensuring proper protection and recognition of the invention’s intellectual property rights.
Pride of Augustinian Research Excellence
This milestone is spearheaded under the Office of the Vice President for Research and Innovation and implemented at the Center for Natural Drug Discovery and Development (CND3) and Center for Chemical Biology and Biotechnology (C2B2), reflecting the university’s strong commitment to advancing high-impact scientific discovery.
This achievement is led by a team of distinguished researchers: Dr. Jonel P. Saludes (director, CND3), Dr. Doralyn S. Dalisay (director, C2B2), Ms. Angelica Faith L. Suarez (CND3), Ms. Melissa June V. Paderog (C2B2), and Ms. Edna M. Sabido (C2B2).
Addressing a Global Health Challenge
Antibiotic resistance continues to threaten modern healthcare systems, reducing the effectiveness of existing treatments and increasing risks of disease spread, severe illness, and mortality. Innovations such as this patented discovery offer promising pathways toward new therapeutic solutions and reinforce the importance of sustained scientific research and development.
Strengthening the University’s Global Research Impact
With this patent, the University of San Agustin strengthens its position in the international scientific community, demonstrating that Filipino researchers are capable of producing world-class innovations that directly contribute to solving global health challenges.
Beyond scientific recognition, this milestone underscores the university’s mission of forming researchers who not only excel in their fields but also create meaningful impact for society.
A Milestone for Science and Nation
This achievement stands as a testament to the power of Philippine research and innovation and the enabling funding support of the Philippine government. More than a patent, it represents a step forward for global health, a recognition of Augustinian excellence, and a proud milestone for the University of San Agustin and the country./PN
